New Research Reveals a Significant Proportion of Bipolar I Disorder Patients
Experience Depressive Symptoms During Mania
VIENNA, October 16, 2012
VIENNA, October 16, 2012 /PRNewswire/ --
The I nvestigating M anic P hases A nd C urrent T rends in Bipolar
(IMPACT) study, which was designed to investigate the effects of periods of
mania in people diagnosed with bipolar I disorder, also found for over
three-quarters of respondents,bipolar I disorder had decreased their own
expectations of success in life.
For media outside China, Japan and USA only.
Lundbecktoday announced results from an international study of people living
with bipolar I disorder, which found a significant proportion of patients
experience symptoms of depression during an episode of mania. ^ The IMPACT
of Bipolar study ( I nvestigating M anic P hases A nd C urrent T rends)
found 64% of people reported experiencing feeling depressed during a manic
episode. ^ Bipolar I disorder, a subset of bipolar disorder, is a chronic,
episodic illnesscharacterisedby mania, depression, or a combination of both.
"Theresults of the global IMPACT of Bipolar study show depression isa
significant factor during mania for a considerable number of bipolar I
patients," said Professor EduardVieta, Director of the Bipolar Disorders
Program Hospital Clinic at the University of Barcelona. "Depressive symptoms
can have a marked impact on patients with bipolar I disorder. This impact is
compounded when the depression also occurs during an episode of mania.
Continued research is critical to improve approaches to effective management."
Bipolar I disorder was also found to have an impact on relationships and the
work lives of respondents with 45% reporting they had lost a job and 38% were
separated or divorced as a result of the disorder. Over three-quarters (76%)
reported that bipolar I disorder had decreased their own expectations of
success in life. ^
"Bipolar I disorder can have a dramatic effect on the lives of those living
with the disorder and their family and friends," said PaulArteel, Executive
Director of the Global Alliance of Mental Illness Advocacy Networks (GAMIAN)
Europe."The IMPACT of Bipolar Study found that a significant number of
participants become more pessimistic about their future after diagnosis which
can have a dramatic affect on their sense of wellbeing."
The IMPACT of Bipolar Study involved 700 respondents in Australia, Canada,
Italy, France, Germany, Spain and the UK,aged18-65 who had been diagnosed
with bipolar I disorder for 12 months or more. The study primarily
investigated the effects of periods of mania in those diagnosed with bipolar I
Bipolar disorder affects 30 million people worldwide including over four
million people in Europe. ^ It is the sixth leading cause of disability
worldwide. ^ People with bipolar disorder are part of a medically-burdened
population that often experience multiple complications.
About bipolar I disorder
Bipolar disorder (also known as manic-depressive disorder) is a chronic,
episodic illness so named because sufferers alternate between two poles of
extreme moods - mania and depression. ^ Bipolar I disorder
ischaracterisedby mania (episodes of elevated moods, extreme irritability,
decreased sleep and increased energy), depression (overwhelming feelings of
sadness, suicidal thoughts), or a combination of both. ^
About IMPACT of Bipolar Study
The I nvestigating M anic P hases A nd C urrent T rends (IMPACT) study
primarily investigated the effects of periods of mania in people diagnosed
with bipolar I disorder. The study involved 700 respondents in Australia,
Canada, Italy, France, Germany, Spain and the UK aged 18-65 who had been
diagnosed with bipolar I disorder for 12 months or more. Respondents
participated in an online questionnaire between March and August 2012. The
study was commissioned byLundbeckLtd and conducted in the UK, Spain, France,
Italy, Germany, Canada and Australia by Phoenix Healthcare International.
Further results of the IMPACT of Bipolar Study are available online at
About Phoenix Healthcare International
Phoenix Healthcare International provides research, marketing and consulting
services to the world's leadingPharma, Biotech, Medical Device, Diagnostic
and HealthcareOrganisations. Phoenix Healthcare International is part
ofPhoenix Marketing International, founded in 1999 and now the 30 ^th
largest market research firm in the most recentHonomichlreport.
H.LundbeckA/S (LUN.CO, LUN DC,HLUKY) is an international pharmaceutical
company highly committed to improving the quality of life for people suffering
from brain disorders. For this purpose,Lundbeckis engaged in the research,
development, production, marketing and sale of pharmaceuticals across the
world. The company's products are targeted at disorders such as depression and
anxiety, psychotic disorders, epilepsy and Huntington's, Alzheimer's and
Lundbeckwas founded in 1915 by HansLundbeckin Copenhagen, Denmark.
TodayLundbeckemploys approximately 6,000 people worldwide.Lundbeckis one
of the world's leading pharmaceutical companies working with brain disorders.
In 2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.2
billion or USD 3.0 billion). For more information, please visit
1 .IMPACT of Bipolar Study 2012 (Data on file)
2 .World Health Organization.Disease incidence, prevalence and
.Accessed August 24, 2012.
3 .Kleinman, L et al. Costs of bipolar
4 .National Institute of Mental Health.Bipolar Disorder 2009.Available at:
. Accessed August 24, 2012.
Contact: Contact: Emmanuelle Weiller, H. Lundbeck A/S, EMWE@lundbeck.com,
Press spacebar to pause and continue. Press esc to stop.